Profibrotic Molecules Are Reduced in CRISPR-Edited Emery-Dreifuss Muscular Dystrophy Fibroblasts
August 2025
in “
Cells
”
TLDR CRISPR gene editing reduces harmful molecules in cells from Emery–Dreifuss Muscular Dystrophy patients.
The study explores the effects of CRISPR/Cas gene editing on fibroblasts and myoblasts from patients with Emery–Dreifuss Muscular Dystrophy (EDMD), focusing on reducing profibrotic molecules like TGFbeta 2 and miR-21. Researchers found that fibroblasts with mutations in EMD and LMNA genes showed increased fibrogenic markers, which were significantly reduced after CRISPR correction. This gene editing restored normal miRNA profiles and emerin expression, suggesting a potential therapeutic approach for managing fibrosis in EDMD. The study involved multiple experiments with triplicate samples, confirming the efficiency and specificity of the gene editing, and highlights the promise of CRISPR technology in treating laminopathies like EDMD.